TapewireFind a company

person · Reporting owner

Palczuk Linda

Disclosed activity across 3 companies

Tapewire entity
66778
SEC CIK
0001717580

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
OSIRIS THERAPEUTICS, INC.OSIR · Entity 158290President & CEOJuly 10, 2017September 21, 2017
Verrica Pharmaceuticals Inc.VRCA · Entity 6823Chief Operating OfficerFebruary 28, 2019March 04, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

OSIRIS THERAPEUTICS, INC.

Report date July 10, 2017 · Filed September 21, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.67 · Expires 2027-07-10Direct25,000 Reported balance After 2017-07-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2017-07-10 · Grant · Acquired 25,000 · Balance 25,000

F1: 6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date.

Verrica Pharmaceuticals Inc.

Report date February 28, 2019 · Filed March 04, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2029-02-27Direct68,260 Reported balance After 2019-02-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-02-28 · Grant · Acquired 68,260 · Balance 68,260

F1: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVADEL PHARMACEUTICALS PLC

Report date February 12, 2026 · Filed February 12, 2026

Section 16 reporting ended · disclosed 2026-02-12. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect0 Reported balance After 2026-02-12 transaction · row 1
1 source row

Row 1 · 2026-02-12 · Disposition to issuer · Disposed 78,905 · Balance 0

F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.

F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").

F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2029-08-07IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-02-12 · Disposition to issuer · Disposed 60,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.48 · Expires 2030-08-07IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.07 · Expires 2031-08-03IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2032-08-03IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-02-12 · Disposition to issuer · Disposed 42,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.10 · Expires 2033-08-01IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-02-12 · Disposition to issuer · Disposed 33,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-07-30IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.93 · Expires 2034-12-17IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-02-12 · Disposition to issuer · Disposed 25,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2035-07-29IndirectBy Trust0 Reported balance After 2026-02-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2026-02-12 · Disposition to issuer · Disposed 11,000 · Balance 0

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.

F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").

F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.

F4: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5: The Options are held by a revocable trust of which the Reporting Person is trustee.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 11,000 Not disclosed Strike: $10.83 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 9

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 11,000 shares

Expires 2035-07-29

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $10.93 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 8

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 25,000 shares

Expires 2034-12-17

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 11,000 Not disclosed Strike: $16.32 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 7

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 11,000 shares

Expires 2034-07-30

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 33,000 Not disclosed Strike: $14.10 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 6

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 33,000 shares

Expires 2033-08-01

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 42,000 Not disclosed Strike: $4.79 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 5

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 42,000 shares

Expires 2032-08-03

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 42,000 Not disclosed Strike: $8.07 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 4

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 42,000 shares

Expires 2031-08-03

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 42,000 Not disclosed Strike: $8.48 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 3

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 42,000 shares

Expires 2030-08-07

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerStock Option (Right to Buy) · Derivative 60,000 Not disclosed Strike: $2.03 Not disclosed
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · derivative · entry 2

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Ordinary Shares · 60,000 shares

Expires 2029-08-07

F4 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

F5 · ownership.nature: The Options are held by a revocable trust of which the Reporting Person is trustee.

Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:35 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 Disposition to issuerOrdinary Shares 78,905 $21.00 $1,657,005.00
Disclosure

SEC source: 0001104659-26-014446 · tm266121-7_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.

F2 · kind: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").

F3 · shares: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.

F1 · price: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.

F2 · price: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").

Read SEC document
September 15, 2025 Filed Sep 15, 2025 19:54 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $10.83 $0.00
Disclosure

SEC source: 0001104659-25-090116 · tm2526163-2_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 11,000 shares

Expires 2035-07-29

F1 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

Read SEC document
July 29, 2025 Filed Jul 31, 2025 16:09 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $10.83 $0.00
Disclosure

SEC source: 0001104659-25-072692 · tm2522138-5_4seq1.xml · derivative · entry 2

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Ordinary Shares · 11,000 shares

Expires 2035-07-29

F2 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

Read SEC document
July 29, 2025 Filed Jul 31, 2025 16:09 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantOrdinary Shares 11,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-072692 · tm2522138-5_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,900

F1 · shares: Represents a restricted share award. The shares shall vest in full on the earlier to occur of (a) July 29, 2026 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

Read SEC document
January 24, 2025 Filed Jan 28, 2025 16:22 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $10.93 $0.00
Disclosure

SEC source: 0001104659-25-006709 · tm254584-1_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 25,000 shares

Expires 2034-12-17

F1 · derivative.exercise_date: The options become exercisable in three equal annual installments on each of the first three anniversaries following the 12/17/2024 grant date, subject to the Reporting Person's continued service at each such vesting date.

Read SEC document
January 21, 2025 Filed Jan 22, 2025 16:13 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 PurchaseOrdinary Shares 5,000 $7.93 $39,640.00
Disclosure

SEC source: 0001104659-25-005248 · tm254051-1_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,900

Read SEC document
December 24, 2024 Filed Dec 27, 2024 16:15 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftOrdinary Shares 3,500 $0.00 $0.00
Disclosure

SEC source: 0001104659-24-132145 · tm2432060-1_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,900

Read SEC document
December 17, 2024 Filed Dec 19, 2024 16:20 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $10.93 $0.00
Disclosure

SEC source: 0001104659-24-130173 · tm2431478-1_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Ordinary Shares · 25,000 shares

Expires 2034-12-17

F1 · derivative.exercise_date: The options become exercisable in three equal annual installments on each of the first three anniversaries following the 12/17/2024 grant date, subject to the Reporting Person's continued service at each such vesting date.

Read SEC document
December 06, 2024 Filed Dec 10, 2024 07:00 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 PurchaseOrdinary Shares 3,000 $10.19 $30,567.60
Disclosure

SEC source: 0001104659-24-126999 · tm2430449-1_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,400

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.18 to $10.1899, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
September 15, 2024 Filed Sep 16, 2024 17:18 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $16.32 $0.00
Disclosure

SEC source: 0001104659-24-100286 · tm2424180-1_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 11,000 shares

Expires 2034-07-30

F1 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant (July 30, 2024), subject to the Reporting Person's continued service at such time.

Read SEC document
July 30, 2024 Filed Aug 1, 2024 16:38 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (Right to Buy) · Derivative 11,000 $0.00 Strike: $16.32 $0.00
Disclosure

SEC source: 0001104659-24-084944 · tm2420652-6_4seq1.xml · derivative · entry 2

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Ordinary Shares · 11,000 shares

Expires 2034-07-30

F2 · derivative.exercise_date: The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

Read SEC document
July 30, 2024 Filed Aug 1, 2024 16:38 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantOrdinary Shares 11,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-24-084944 · tm2420652-6_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,400

F1 · shares: Represents restricted share units ("RSUs"). Each RSU represents the contingent right to receive one Ordinary Share upon vesting and settlement. The RSUs shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.

Read SEC document
September 01, 2023 Filed Sep 1, 2023 21:30 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 33,000 $0.00 Strike: $14.10 $0.00
Disclosure

SEC source: 0001104659-23-097892 · tm2325379-2_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: ADSs · 33,000 shares

Expires 2033-08-01

F1 · derivative.exercise_date: These options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant (August 1, 2023), subject to the Reporting Person's continued service on the Board of Directors at such time.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
August 01, 2023 Filed Aug 3, 2023 16:16 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (Right to Buy) · Derivative 33,000 $0.00 Strike: $14.10 $0.00
Disclosure

SEC source: 0001104659-23-087286 · tm2322778-2_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,000

Underlying: ADSs · 33,000 shares

Expires 2033-08-01

F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
May 09, 2023 Filed May 10, 2023 16:12 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 PurchaseADSs 2,500 $14.76 $36,900.00
Disclosure

SEC source: 0001104659-23-058439 · tm2315307-1_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,400

F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
January 20, 2023 Filed Jan 24, 2023 17:00 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 42,000 $0.00 Strike: $4.79 $0.00
Disclosure

SEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 7

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: ADSs · 42,000 shares

Expires 2032-08-03

F5 · derivative.exercise_date: These options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
January 20, 2023 Filed Jan 24, 2023 17:00 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 42,000 $0.00 Strike: $8.07 $0.00
Disclosure

SEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 5

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: ADSs · 42,000 shares

Expires 2031-08-03

F1 · derivative.exercise_date: These options are fully vested and exercisable as of the date hereof.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
January 20, 2023 Filed Jan 24, 2023 17:00 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 42,000 $0.00 Strike: $8.48 $0.00
Disclosure

SEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 3

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: ADSs · 42,000 shares

Expires 2030-08-07

F4 · derivative.exercise_date: These options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date, subject to the Reporting Person's continued service at each such vesting date.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
January 20, 2023 Filed Jan 24, 2023 17:00 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GiftStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $2.03 $0.00
Disclosure

SEC source: 0001104659-23-006235 · tm234325-1_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: ADSs · 60,000 shares

Expires 2029-08-07

F1 · derivative.exercise_date: These options are fully vested and exercisable as of the date hereof.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
December 23, 2022 Filed Dec 28, 2022 16:02 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 PurchaseADSs 2,000 $7.20 $14,405.00
Disclosure

SEC source: 0001104659-22-130515 · tm2233557-1_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,900

F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
August 03, 2022 Filed Aug 5, 2022 17:12 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (Right to Buy) · Derivative 42,000 $0.00 Strike: $4.79 $0.00
Disclosure

SEC source: 0001104659-22-086771 · tm2222707-2_4seq1.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: ADSs · 42,000 shares

Expires 2032-08-03

F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
May 27, 2022 Filed May 31, 2022 07:17 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 PurchaseADSs 10,000 $1.60 $16,000.00
Disclosure

SEC source: 0001104659-22-066227 · tm2217241-4_4seq1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,900

F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
August 03, 2021 Filed Aug 5, 2021 19:26 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (Right to Buy) · Derivative 42,000 $0.00 Strike: $8.07 $0.00
Disclosure

SEC source: 0001179110-21-007964 · edgar.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: ADSs · 42,000 shares

Expires 2031-08-03

F1 · derivative.exercise_date: Options shall vest in full on the earlier to occur of (a) August 3, 2022 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.

F2 · derivative.underlying: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
August 14, 2020 Filed Aug 17, 2020 18:58 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 PurchaseADS 2,500 $7.94 $19,849.75
Disclosure

SEC source: 0001179110-20-009084 · edgar.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,900

F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

F2 · balance_after: Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.

Read SEC document
August 07, 2020 Filed Aug 11, 2020 16:56 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (Right to Buy) · Derivative 42,000 $0.00 Strike: $8.48 $0.00
Disclosure

SEC source: 0001179110-20-008889 · edgar.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: ADSs · 42,000 shares

Expires 2030-08-07

F1 · derivative.exercise_date: Options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date.

F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
December 03, 2019 Filed Dec 5, 2019 16:29 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 PurchaseADSs 7,500 $5.91 $44,325.00
Disclosure

SEC source: 0001104659-19-070213 · tm19244822_form4.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,400

F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

F2 · balance_after: Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.

Read SEC document
August 07, 2019 Filed Aug 9, 2019 17:00 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantStock Option (right to buy) · Derivative 60,000 $0.00 Strike: $2.03 $0.00
Disclosure

SEC source: 0001567619-19-016166 · doc1.xml · derivative · entry 2

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: ADSs · 60,000 shares

Expires 2029-08-07

F3 · derivative.exercise_date: Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date.

F1 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Read SEC document
February 28, 2019 Filed Mar 4, 2019 17:31 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 GrantEmployee Stock Option (Right to Buy) · Derivative 68,260 $0.00 Strike: $11.32 $0.00
Disclosure

SEC source: 0001209191-19-015814 · doc4.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,260

Underlying: Common Stock · 68,260 shares

Expires 2029-02-27

F1 · derivative.exercise_date: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date.

Read SEC document
January 16, 2019 Filed Jan 17, 2019 16:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 PurchaseCommon Stock 3,000 $10.53 $31,590.00
Disclosure

SEC source: 0001209191-19-004240 · doc4.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.40 to $10.659, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.direct: Consists of 3,000 shares of common stock held by Ms. Palczuk and 5,500 shares of common stock held by Ms. Palczuk jointly with her spouse.

Read SEC document
September 17, 2018 Filed Sep 18, 2018 16:27 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 PurchaseCommon Stock 2,500 $16.52 $41,300.00
Disclosure

SEC source: 0001209191-18-051471 · doc4.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,500

F1 · price: This transaction was executed in multiple trades at prices ranging from $16.52 to $16.55, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.direct: Consists of 3,000 shares of common stock held by Ms. Palczuk and 2,500 shares of common stock held by Ms. Palczuk jointly with her spouse.

Read SEC document
August 01, 2018 Filed Aug 2, 2018 16:17 UTC AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 GrantADSs 27,900 $0.00 $0.00
Disclosure

SEC source: 0001140361-18-035136 · doc1.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,900

F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

F2 · shares: Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 08/01/2018; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.

Read SEC document
June 19, 2018 Filed Aug 15, 2018 16:48 UTC Verrica Pharmaceuticals Inc. VRCA · Entity 6823 PurchaseCommon Stock 3,000 $15.00 $45,000.00
Disclosure

SEC source: 0001209191-18-046827 · doc4.xml · nonDerivative · entry 1

Palczuk Linda · CIK 0001717580 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Read SEC document
July 10, 2017 Filed Sep 21, 2017 15:54 UTC OSIRIS THERAPEUTICS, INC. OSIR · Entity 158290 GrantIncentive Stock Option (right to buy) · Derivative 25,000 $6.67 Strike: $6.67 $166,750.00
Disclosure

SEC source: 0001123292-17-001439 · edgar.xml · derivative · entry 1

Palczuk Linda · CIK 0001717580 · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-07-10

F1 · derivative.exercise_date: 6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.